Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00140075
Status:
COMPLETED
Last Update Posted:
2011-05-26
First Post:
2005-08-29
Brief Title:
Adjuvant EpirubicinCytoxan Followed By A Taxane VS EpirubicinTaxane As Treatment For Node-Positive Breast Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase III Randomized Study Of EpirubicinCyclophosphamide Followed By Taxane Sequential Chemotherapy Versus EpirubicinTaxane Concurrent Chemotherapy As Adjuvant Treatment For Operable Node-Positive Breast Cancer
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare two combinations of drugs epirubicin given with a taxane ET or epirubicin given with cyclophosphamide cytoxan and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years The study will also evaluate the side effects of both treatment combinations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None